With value-based insurance design, cost sharing is still used, but a "clinically sensitive" approach is designed to mitigate the adverse health consequences of high out-of-pocket costs.
Urgent solutions range from re-engineering of the macroeconomic basis of cancer costs (eg, value-based approaches to bend the cost curve and allow cost-saving technologies), greater education of policy makers, and an informed and transparent regulatory system.
In this paper, we consider a dollar-value based cost, but it can be easily modified to other cost considerations as well.
Urgent solutions to contain those costs are necessary and range from re-engineering the macroeconomic basis of cancer spending (e.g. value-based approaches to bend the cost curve and allow cost saving technologies), educating policy makers, introducing transparent and equitable regulatory systems, and adopting validated outcomes in both clinical trials and processes of drug approval [ 1, 2].
A growing base of research indicates that a large proportion of cost and value-based innovations are coming from emerging markets – an opportunity for learning which is not evident in the work of Canadian innovators or health systems [ 7].
Unlike traditional health care plan designs, value-based insurance design tailors the cost of care delivery to the benefit that a patient or class of patients derives from that care.
It is shown that the three methods for calculating the value impact render different results suggesting that the use of a single method to assess forecast development scenarios, whether cost or value-based methods, may be misleading and that the holistic approach proposed is more realistic.
Several value-based initiatives aim to minimize cost in areas of increased spending and promote rationalization of resource allocation [ 1].
In accordance with the paradigm of value-based management, the consideration of costs, benefits and risks when deciding on an investment is necessary, plausible, and an accepted standard.
However, previous approaches have not handled requirement interactions, such as the dependencies that may exist between requirements, and, or, precedence, cost- and value-based constraints.
A gradual change from cost pricing to value-based pricing may provide a scientific and rational drug pricing policy for off-patent originators.
